A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2002
12/12/2002	US20020187930 Substances and their uses
12/12/2002	US20020187923 Antidiabetic agent; hyperglycemic agents
12/12/2002	US20020187542 Fatty-acid amide hydrolase
12/12/2002	US20020187534 Treating cancer by increasing intracellular malonyl CoA levels
12/12/2002	US20020187523 Extracellular signaling molecules
12/12/2002	US20020187197 Templating of solid particles by polymer multilayers
12/12/2002	US20020187191 Oxidized collagen formulations for use with non-compatible pharmaceutical agents
12/12/2002	US20020187172 Polymeric material associated with colloidal metal particles, especially gold, suitable for injection or implantation.
12/12/2002	US20020187149 Activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptible carrier.
12/12/2002	US20020187101 Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes
12/12/2002	DE10125883A1 Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie Medicines containing an effector of the glutathione metabolism together with alpha-lipoic acid in the context of renal replacement therapy
12/12/2002	DE10125882A1 Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Behandlung des Diabetes mellitus Medicines containing an effector of the glutathione metabolism together with alpha-lipoic acid in the treatment of diabetes mellitus
12/12/2002	CA2449843A1 Non-peptide gnrh agents, pharmaceutical compositions and methods for their use, and processes for preparing them
12/12/2002	CA2449813A1 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
12/12/2002	CA2449771A1 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
12/12/2002	CA2449658A1 Use of rank antagonists to treat cancer
12/12/2002	CA2449487A1 Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
12/12/2002	CA2449482A1 Chds as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449466A1 Peripheral blood fibrocytes differentiation pathway and migration to wound sites
12/12/2002	CA2449425A1 Slc2as as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449289A1 Gfats as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449281A1 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449275A1 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449270A1 Pibs as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449267A1 Hs2sts as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449206A1 Cads as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449175A1 Use of methylnaltrexone to treat immune suppression
12/12/2002	CA2449136A1 Igs as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449135A1 Adsls as modifiers of the p53 pathway and methods of use
12/12/2002	CA2449109A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002	CA2449097A1 5-ethyl-imidazotriazinones
12/12/2002	CA2449021A1 Novel compounds and compositions as cathepsin inhibitors
12/12/2002	CA2449008A1 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
12/12/2002	CA2448834A1 Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
12/12/2002	CA2448665A1 Sustained-release analgesic compounds
12/12/2002	CA2448418A1 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
12/12/2002	CA2448382A1 Use of hepcidin as a regulator of iron homeostasis
12/12/2002	CA2448282A1 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002	CA2448250A1 Limks as modifiers of the p53 pathway and methods of use
12/12/2002	CA2448107A1 Marks as modifiers of the p53 pathway and methods of use
12/12/2002	CA2447935A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
12/12/2002	CA2447746A1 Cycloalkenylsulfonamide derivatives
12/12/2002	CA2447732A1 Antineoplastic combinations
12/12/2002	CA2447480A1 Pyranoindazoles and their use for the treatment of glaucoma
12/12/2002	CA2447479A1 Novel arylaminopropane analogues and their use for the treatment of glaucoma
12/12/2002	CA2447156A1 Novel fused indazoles and indoles and their use for the treatment of glaucoma
12/12/2002	CA2446929A1 Orally administering parathyroid hormone and calcitonin
12/12/2002	CA2446716A1 Sulfonamide derivatives
12/12/2002	CA2446696A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
12/12/2002	CA2446160A1 Combination comprising a p-gp inhibitor and an anti-epileptic drug
12/12/2002	CA2445460A1 Carboline derivatives as pde-5 inhibitors
12/12/2002	CA2438099A1 Trifluoromethylpurines as phosphodiesterase 4 inhibitors
12/12/2002	CA2436408A1 Modified psma ligands and uses related thereto
12/12/2002	CA2418088A1 Numb protein expression inhibitors by musashi 1
12/11/2002	WO2001083471A1 Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
12/11/2002	EP1264884A1 Method of controlling telomere length
12/11/2002	EP1264829A1 Oxygen-containing heterocyclic compounds
12/11/2002	EP1264828A1 New inhibitor of urokinase
12/11/2002	EP1264827A1 Process for the preparation of Tosylbenzylformamides
12/11/2002	EP1264599A1 TNF-derived peptides for use in treating oedema
12/11/2002	EP1264597A2 Methods and compositions for treating cancer
12/11/2002	EP1263960A2 Anti-tissue factor antibodies with enhanced anticoagulant potency
12/11/2002	EP1263959A1 Antibodies to human cd154
12/11/2002	EP1263958A2 Nusap, a gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent
12/11/2002	EP1263955A2 Polypeptides and nucleic acids encoding same
12/11/2002	EP1263948A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/11/2002	EP1263943A1 Protein c derivatives
12/11/2002	EP1263940A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
12/11/2002	EP1263933A2 Treatment for bone disorders
12/11/2002	EP1263932A1 Embryonic stem cells and neural progenitor cells derived therefrom
12/11/2002	EP1263930A1 Human cord blood as a source of neural tissue for repair of the brain and spinal cord
12/11/2002	EP1263786A2 Methods and compositions for immunoregulation
12/11/2002	EP1263784A1 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
12/11/2002	EP1263775A1 Hla binding peptides and their uses
12/11/2002	EP1263774A2 Gamma-secretase inhibitors
12/11/2002	EP1263766A1 Adam polynucleotides, polypeptides, and antibodies
12/11/2002	EP1263765A1 ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
12/11/2002	EP1263763A2 Tubulin binding ligands and corresponding prodrug constructs
12/11/2002	EP1263762A1 Anti-infective ectatm
12/11/2002	EP1263760A1 Novel compounds
12/11/2002	EP1263759A2 Azaindoles
12/11/2002	EP1263757A1 Benzthiazoles as tnf and pde-iv inhibitors
12/11/2002	EP1263756A2 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
12/11/2002	EP1263755A2 Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
12/11/2002	EP1263753A1 Imidazol derivatives as raf kinase inhibitors
12/11/2002	EP1263752A2 Lpa receptor agonists and antagonists and methods of use
12/11/2002	EP1263747A1 1,5-benzothiazepines and their use as hypolipidaemics
12/11/2002	EP1263745A1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
12/11/2002	EP1263743A1 Heterocycle substituted diphenyl leukotriene antagonists
12/11/2002	EP1263740A1 Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
12/11/2002	EP1263739A1 Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
12/11/2002	EP1263733A2 Derivatives of quinoline as alpha-2 antagonists
12/11/2002	EP1263732A1 Corticotropin releasing factor antagonists
12/11/2002	EP1263730A1 Amine derivatives for the treatment of apoptosis
12/11/2002	EP1263729A1 Azacyclic compounds for use in the treatment of serotonin related diseases
12/11/2002	EP1263728A2 Pde iv inhibiting amides, compositions and pharmaceutical use
12/11/2002	EP1263726A1 N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
12/11/2002	EP1263725A1 Novel compounds
12/11/2002	EP1263724A1 Novel compounds
12/11/2002	EP1263723A1 Ningalin b analogs employable for reversing multidrug resistance

1 ... 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 ... 1564